Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2008.122119v1, 2009; 10.1373/clinchem.2008.122119
This Article
Right arrow Full Text (PDF)
Right arrow HTML Page - index.htslp
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Schwilke, E. W.
Right arrow Articles by Huestis, M. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwilke, E. W.
Right arrow Articles by Huestis, M. A.

Received on December 5, 2008
Accepted on September 22, 2009

Drug Monitoring and Toxicology

{Delta}9-Tetrahydrocannabinol (THC), 11-Hydroxy-THC, and 11-Nor-9-carboxy-THC Plasma Pharmacokinetics During and After Continuous High-Dose Oral THC

Eugene W. Schwilke 1, David M. Schwope 1, Erin L. Karschner 1, Ross H. Lowe 1, William D. Darwin 1, Deanna L. Kelly 2, Robert S. Goodwin 1, David A. Gorelick 3, Marilyn A. Huestis 1*

1 Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, NIH, Biomedical Research Center, 251 Bayview Blvd., Suite 200, Baltimore, MD
2 Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD
3 Office of the Scientific Director, Intramural Research Program, National Institute on Drug Abuse, NIH, Biomedical Research Center, 251 Bayview Blvd., Suite 200, Baltimore, MD

* To whom correspondence should be addressed. E-mail: mhuestis{at}intra.nida.nih.gov.

BACKGROUND: {Delta}9-Tetrahydrocannabinol (THC) is the primary psychoactive constituent of cannabis and an active cannabinoid pharmacotherapy component. No plasma pharmacokinetic data after repeated oral THC administration are available.

METHODS: Six adult male daily cannabis smokers resided on a closed clinical research unit. Oral THC capsules (20 mg) were administered every 4–8 h in escalating total daily doses (40–120 mg) for 7 days. Free and glucuronidated plasma THC, 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH) were quantified by 2-dimensional GC-MS during and after dosing.

RESULTS: Free plasma THC, 11-OH-THC, and THCCOOH concentrations 19.5 h after admission (before controlled oral THC dosing) were mean 4.3 (SE 1.1), 1.3 (0.5), and 34.0 (8.4) μg/L, respectively. During oral dosing, free 11-OH-THC and THCCOOH increased steadily, whereas THC did not. Mean peak plasma free THC, 11-OH-THC, and THCCOOH concentrations were 3.8 (0.5), 3.0 (0.7), and 196.9 (39.9) μg/L, respectively, 22.5 h after the last dose. Escherichia coli {beta}-glucuronidase hydrolysis of 264 cannabinoid specimens yielded statistically significant increases in THC, 11-OH-THC, and THCCOOH concentrations (P < 0.001), but conjugated concentrations were underestimated owing to incomplete enzymatic hydrolysis.

CONCLUSIONS: Plasma THC concentrations remained >1 μg/L for at least 1 day after daily cannabis smoking and also after cessation of multiple oral THC doses. We report for the first time free plasma THC concentrations after multiple high-dose oral THC throughout the day and night, and after Escherichia coli {beta}-glucuronidase hydrolysis. These data will aid in the interpretation of plasma THC concentrations after multiple oral doses.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by the American Association for Clinical Chemistry.